Core Insights - Galapagos NV reported a pivotal year in 2025, focusing on a strategic transformation to enhance long-term value creation, particularly through business development and collaboration with Gilead [2][3] - The company is winding down its cell therapy activities, which is expected to be substantially completed by the end of Q3 2026, allowing for a leaner organization focused on sustainable growth [6][9] - Financially, Galapagos ended 2025 with approximately €3.0 billion in cash and financial investments, and anticipates a year-end cash position for 2026 between €2.775 billion and €2.850 billion [3][24] Financial Performance - Total net revenues for 2025 reached €1,112.2 million, a significant increase of 304% compared to €275.6 million in 2024, driven by collaboration revenues from Gilead [10][13] - Operating profit from continuing operations was €295.1 million in 2025, a turnaround from an operating loss of €188.3 million in 2024, primarily due to revenue recognition from the drug discovery platform [12][13] - The company reported a net profit of €320.9 million for 2025, compared to a net profit of €74.1 million in 2024, reflecting strong financial performance [18] Cash and Investments - Cash and financial investments totaled €2,998.0 million at the end of 2025, down from €3,317.8 million at the end of 2024, with a notable increase in U.S. dollar holdings [19][20] - The net decrease in cash and financial investments for 2025 was €319.8 million, an improvement from a net decrease of €366.7 million in 2024 [20] Strategic Focus - The company aims to build a pipeline of novel therapeutics through disciplined capital allocation and is focused on transformative business development opportunities in areas of high unmet medical need [2][6] - Galapagos expects to be cash flow neutral to positive by the end of 2026, excluding business development activities and currency fluctuations [24] Upcoming Events - A conference call is scheduled for February 24, 2026, to discuss the financial results and strategic direction [26]